NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against XBiotech Inc. (“XBiotech” or the “Company”) (Nasdaq:XBIT) and certain of its present and former officers in the United District Court for the Western District of Texas on behalf of a class consisting of all persons or entities who purchased XBiotech securities between April 15, 2015 through November 23, 2015, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that Defendants issued materially false and misleading statements to investors and/or failed to disclose that: (i) a fewer number of per protocol patients were available for primary endpoint evaluation in the Phase III Study; (ii) the data from 72 patients of the Phase III Study was compromised; (iii) XBiotech did not adequately sample patients to accommodate data loss; (iv) as a result of not properly sampling patients for the Phase III Study, the Phase III Study would have reduced statistical power to demonstrate the proposed outcome; and (v) as a result of the foregoing, Defendants’ statements about its business, operations, and prospects, including statements about the Phase III Study and clinical development of Xilonix, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you wish to serve as lead plaintiff, you must move the Court no later than February 1, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, or to discuss your rights or interests regarding this class action, please contact Thomas J. McKenna, Esq. or Gregory M. Egleston, Esq. of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected].
Please visit our website at http://www.gme-law.com for more information about the firm.


BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Bank of America's $72.5M Epstein Settlement: What You Need to Know
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 



